Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
124 Results for "
integrin αv
" in MedChemExpress (MCE) Product Catalog:
Products (124)
124 Results for "integrin αv" in MCE Product Catalog:
Cat. No.: HY-W008201
CAS No.: 59379-02-1
Cat. No.: HY-P1187
CAS No.: 848644-86-0
Cat. No.: HY-P5021
CAS No.: 756500-22-8
Synonyms: c(RGDfE)
Cat. No.: HY-P1189A
Category:
Natural Products Animals Metabolic Disease Disease Research Fields Inflammation/Immunology
Target:
Cat. No.: HY-P11339
CAS No.: 841255-57-0
Cat. No.: HY-19306
CAS No.: 205678-26-8
SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with Kis of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC50s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression .
Cat. No.: HY-161730
Target:
Research Areas:
αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect .
Cat. No.: HY-P0178A
Target:
Research Areas:
Cat. No.: HY-D2439
Cat. No.: HY-164429
CAS No.: 2418533-90-9
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .
Cat. No.: HY-153807
CAS No.: 313709-47-6
Target:
Research Areas:
αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC50 of 96.5 nM (WO2020081154A1, example 19) .
Cat. No.: HY-175323
Target:
Research Areas:
Cat. No.: HY-P1613
CAS No.: 137813-35-5
Synonyms: Cyclo(RGDfV); C(RGDfV)
Cat. No.: HY-P11339A
Cat. No.: HY-W008859R
CAS No.: 67-30-1
Synonyms: Tetraiodothyroacetic acid (Standard); 3,3',5,5'-Tetraiodothyroacetic acid (Standard)
Cat. No.: HY-172494A
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .
Cat. No.: HY-P0023F1
Target:
Research Areas:
Cat. No.: HY-16141R
CAS No.: 188968-51-6
Synonyms: EMD 121974 (Standard)
Cilengitide (Standard) (EMD 121974 (Standard)) is the analytical standard of Cilengitide (HY-16141). This product is intended for research and analytical applications. Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
Cat. No.: HY-168087
CAS No.: 1893340-21-0
Target:
Research Areas:
GSK3335103 is an orally active non-peptidic αvβ6 integrin inhibitor with a pIC50 of 8 and a pKi of 9.96. GSK3335103 blocks αvβ6 integrin-mediated cell adhesion and TGF-β1 activation, induces integrin internalization, recycling and lysosomal degradation, attenuates TGFβ signaling and reduces collagen deposition. GSK3335103 decreases the level of pSmad2 in BAL cells and collagen deposition in lung tissues in a mouse model of pulmonary fibrosis. GSK3335103 can be used in research related to pulmonary fibrosis .
Cat. No.: HY-P10320
Synonyms: Tumstatin (69-88), human
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
